@PMLiVEcom

News & analysis of healthcare, pharma and biotech. Magazines, directories, profiles, jobs & awards.

 Surrey, UK
pmlive.com/pme
Joined June 2009
  • Tweets22.5K
  • Following3.3K
  • Followers15.6K
648Media
ANTHEM strengthens team with three appointments following Healthy Influence launch pmlive.com/pmhub/bedrock/ant…

ANTHEM strengthens team with three appointments following Healthy Influence launch - PMLiVE

Healthcare communications consultancy welcomes new talent as it invests in its next phase of growth

pmlive.com
29
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo pmlive.com/pharma_news/abbvi…

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo - PMLiVE

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

pmlive.com
148
Who’s steering? Why pharma needs humans at the helm of AI pmlive.com/pharma_news/whos-…

Who’s steering? Why pharma needs humans at the helm of AI - PMLiVE

Understanding how AI decisions are made, who owns the outcomes and how accountability travels across partners and platforms

pmlive.com
123
“We’ve been told we can’t touch AI” pmlive.com/pmhub/11_london/w…

"We've been told we can't touch AI" - PMLiVE

It's not been a great few weeks for anyone trying to make the calm, sensible case for AI tools. Researchers have been quitting the big labs, including

pmlive.com
100
Your AI pilot works. That’s the problem. pmlive.com/pmhub/11_london/y…

Your AI pilot works. That's the problem. - PMLiVE

What breaks when you scale it won't be the model. It'll be your data.

pmlive.com
83
Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy pmlive.com/pmhub/genesis_res…

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical...

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will reshape orphan...

pmlive.com
81
Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss pmlive.com/pharma_news/regen…

Regeneron announces results for preventing lean mass and muscle loss during GLP-1 weight loss -...

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

pmlive.com
145
The impact of AI and digital health on chronic diseases pmlive.com/pharma_news/the-i…

The impact of AI and digital health on chronic diseases - PMLiVE

Over the past decades, advances in information technology have fundamentally transformed the management of chronic diseases, but what impact is this having on the pharma industry?

pmlive.com
1
125
Regulatory complexity: the challenges of navigating the new normal pmlive.com/pharma_news/regul…

Regulatory complexity: the challenges of navigating the new normal - PMLiVE

How functional service provider models are helping pharma adapt to regulatory uncertainty

pmlive.com
107
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo pmlive.com/pharma_news/pfize…

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo - PMLiVE

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

pmlive.com
102
What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness pmlive.com/pmhub/medscape_ed…

What 90 Minutes of Live AI Case Practice Revealed About Physician Readiness - PMLiVE

At EHA 2026 in Stockholm, 425 hematologists and oncologists attended an independent, 90-minute Medscape symposium on the practical and ethical use of AI. The format was case-based. The faculty...

pmlive.com
147
AstraZeneca opens new global strategic R&D centre in US pmlive.com/pharma_news/astra…

AstraZeneca opens new global strategic R&D centre in US - PMLiVE

The new centre will be home to nearly 2,000 world-class researchers and scientists

pmlive.com
1
205
From ambition to action: realising the true value of health pmlive.com/pharma_news/from-…

From ambition to action: realising the true value of health - PMLiVE

Why industry needs to engage earlier, explain value more clearly, understand service pressures and take shared responsibility for implementation

pmlive.com
127
On GLOBE Final Rule pmlive.com/pmhub/genesis_res…

On GLOBE Final Rule - PMLiVE

The publication of the GLOBE Final Rule provides important clarity on the administration's approach to MFN pricing and what it could mean for pharmaceutical pricing, reimbursement, and access...

pmlive.com
147
CPHI Pharma Awards 2026 winners announced in Milan pmlive.com/pharma_news/cphi-…

CPHI Pharma Awards 2026 winners announced in Milan - PMLiVE

The annual awards recognise excellence across 15 categories spanning innovation, manufacturing, sustainability and leadership

pmlive.com
132
Alexion and Aide Health launch app for people with rare diseases pmlive.com/pharma_news/alexi…

Alexion and Aide Health launch app for people with rare diseases - PMLiVE

More than 3.5 million people in the UK live with a rare condition

pmlive.com
123
Rethinking Prenatal Migraine Management: The Clinical Case for Neuromodulation pmlive.com/pmhub/medscape_ed…

Rethinking Prenatal Migraine Management: The Clinical Case for Neuromodulation - PMLiVE

Disclaimer: Management of migraine in pregnancy typically combines lifestyle strategies, nonpharmacologic approaches, selected pharmacologic options when benefits outweigh risks, and, increasingly,...

pmlive.com
2
176
Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog pmlive.com/pharma_news/chies…

Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog - PMLiVE

An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease

pmlive.com
123
Biogen announces phase 2 data for cutaneous lupus erythematosus pmlive.com/pharma_news/bioge…

Biogen announces phase 2 data for cutaneous lupus erythematosus - PMLiVE

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

pmlive.com
160
Invited, but not equipped: patient involvement needs more than an open door pmlive.com/pmhub/cuttsycutts…

Invited, but not equipped: patient involvement needs more than an open door - PMLiVE

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

pmlive.com
147
Load more